Crohn's and Colitis 360 : Impact Factor & More
eISSN: 2631-827XpISSN: 2631-827X
Open AccessShare this on:
Key Metrics
CiteScore 
1
SNIP
0.35
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Crohn's and Colitis 360 Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | OXFORD UNIV PRESS |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | USD 2975 |
| Publication Time | 12 |
| Editorial Review Process | Double anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Crohn's and Colitis Foundation |
| Frequency | Quarterly |
| Publication Start Year | 2019 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Crohn's and Colitis 360 ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Crohn's and Colitis 360
Voluntary childlessness and family planning in men with inflammatory bowel disease: a scoping review
- 1 Jun 2026
- 1 Jan 0360
Long-term treatment outcomes of upadacitinib for Crohn\u2019s disease: a single-center retrospective study
- 29 May 2026
- 1 Jan 0360
A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis
- 26 May 2026
- 1 Jan 0360
Effectiveness and safety of extended upadacitinib induction therapy in adult patients with moderate-to-severe active ulcerative colitis
- 21 May 2026
- 1 Jan 0360
Correction to:\xa0Patients\u2019 attitudes to disease prevention in inflammatory bowel disease: a US-based survey
- 20 May 2026
- 1 Jan 0360
A real-world observational study of second-line anti-TNF\u03b1 treatment in patients with ulcerative colitis who received vedolizumab as a first-line biologic
- 15 May 2026
- 1 Jan 0360
Voluntary childlessness and family planning in men with inflammatory bowel disease: a scoping review
- 1 Jun 2026
- 1 Jan 0360
Long-term treatment outcomes of upadacitinib for Crohn\u2019s disease: a single-center retrospective study
- 29 May 2026
- 1 Jan 0360
A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis
- 26 May 2026
- 1 Jan 0360
Effectiveness and safety of extended upadacitinib induction therapy in adult patients with moderate-to-severe active ulcerative colitis
- 21 May 2026
- 1 Jan 0360
Correction to:\xa0Patients\u2019 attitudes to disease prevention in inflammatory bowel disease: a US-based survey
- 20 May 2026
- 1 Jan 0360
A real-world observational study of second-line anti-TNF\u03b1 treatment in patients with ulcerative colitis who received vedolizumab as a first-line biologic
- 15 May 2026
- 1 Jan 0360
FAQs on Crohn's and Colitis 360
How long has Crohn's and Colitis 360 been actively publishing? 
What is the publishing frequency of Crohn's and Colitis 360?
How many articles did Crohn's and Colitis 360 publish last year?
What is the eISSN & pISSN for Crohn's and Colitis 360?
What is Citescore for Crohn's and Colitis 360?
What is SNIP score for Crohn's and Colitis 360?
Who is the publisher of Crohn's and Colitis 360?
